BioSpace News Archive

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will present the updated interim data from the ongoing phase Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of Eve E. Slater, M.D., F.A.C.C., to the Company’s Board of Directors

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical firm focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) has announced the expansion of its U.S. presence and workforce ahead of potential Food and Drug Administration (“FDA”) approval of arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”).

AireHealth, an innovative digital health company empowering and improving healthy living through affordable treatments, symptom tracking and early detection of respiratory conditions, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its connected nebulizer

Researchers from Case Western Reserve University presented research Saturday in which Hemex Health’s Gazelle platform diagnostic technology successfully tested 46 patients with 100% sensitivity and over 92.3% specificity for anemia and with 100% accuracy for hemoglobin variants.

Katena Products (“Katena”), a leading provider of ophthalmic instruments, biologics, and devices, is pleased to announce that Steve Blazejewski has joined as Chief Executive Officer.

IQVIA™ said that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies.

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Friday, December 4, 2020 the Company entered into a commercial manufacturing and supply framework agreement (the “CMO Agreement”) with the Company’s partner in China, Qilu Pharmaceutical Co., Ltd. (“Qilu”).

Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that it has closed its Series A round of financing with $20 million, led by Bow Capital and joined by Andreessen Horowitz, which led its $5 million seed round